A Randomized, Open-label, Phase 3 Study of Carfilzomib Plus Dexamethasone vs. Bortezomib Plus Dexamethasone in Patients With Relapsed Multiple Myeloma

Trial Profile

A Randomized, Open-label, Phase 3 Study of Carfilzomib Plus Dexamethasone vs. Bortezomib Plus Dexamethasone in Patients With Relapsed Multiple Myeloma

Completed
Phase of Trial: Phase III

Latest Information Update: 06 Jul 2018

At a glance

  • Drugs Carfilzomib (Primary) ; Bortezomib; Bortezomib; Dexamethasone
  • Indications Bone marrow disorders; Multiple myeloma
  • Focus Registrational; Therapeutic Use
  • Acronyms ENDEAVOR
  • Sponsors Amgen; Onyx Pharmaceuticals
  • Most Recent Events

    • 17 Jun 2018 Results of an indirect comparison and exploratory analysis presented at the 23rd Congress of the European Haematology Association
    • 05 Jun 2018 Results of a subgroup analysis presented at the 54th Annual Meeting of the American Society of Clinical Oncology.
    • 05 Jun 2018 Results assessing time to deterioration in health-related quality of life presented at the 54th Annual Meeting of the American Society of Clinical Oncology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top